Page last updated: 2024-10-28

ifosfamide and HIV

ifosfamide has been researched along with HIV in 1 studies

HIV: Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Reid, EG1
Looney, D1
Maldarelli, F1
Noy, A1
Henry, D1
Aboulafia, D1
Ramos, JC1
Sparano, J1
Ambinder, RF1
Lee, J1
Cesarman, E1
Yahyaei, S1
Mitsuyasu, R1
Wachsman, W1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Safety and Efficacy Pilot Trial of the Anti-Viral and Anti-Tumor Activity of Velcade Combined With (R)ICE in Subjects With EBV and/or HHV-8 Positive Relapsed/Refractory AIDS-Associated Non-Hodgkin's Lymphoma[NCT00598169]Phase 123 participants (Actual)Interventional2007-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trials

1 trial available for ifosfamide and HIV

ArticleYear
Safety and efficacy of an oncolytic viral strategy using bortezomib with ICE/R in relapsed/refractory HIV-positive lymphomas.
    Blood advances, 2018, 12-26, Volume: 2, Issue:24

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; APOBEC-3G Deaminase; Bortezomib; Carbop

2018